

Review of: "[Research Note] Semaglutide, a GLP-1 Agonist Like Ozempic, and Its Potential Role as a Preventive Anti-Cancer Agent"

Sebastian Cuesta¹

¹ The University of Manchester

Potential competing interests: No potential competing interests to declare.

The research needs careful revision before it can be publish:

- The author said Semaglutide is like Ozempic, but Semaglutide is the chemical name and Ozempic is the trade name so they are the same.
- With the increasing missuse of drugs including the same Ozempic, the author should avoid the use of the word preventive in the note as it should not be taken without an especialist approval.
- Semaglutide is not mention anymore in the research note which is weird as the title is about it
- Some graphs can be added to improve quality.
- Why Author talks about exenatide if the note is about Semaglutide.